RAC-GS Online Practice Questions and Answers

Company X encounters challenges in the global life cycle management of its medical devices. Which of the following Is MOST appropriate for improving product life cycle management?

A. Utilize the STED template to complete global requirements.

B. Initiate a global submission process after all submission data are finalized.

C. Identify countries where special requirements exist during the product development phase.

D. Plan regulatory approval update meetings with senior management and stakeholders.

A company is developing a new product for the global market. A new international guideline will recommend relevant studies in the pediatric population, and the guideline will be effective before the approval of the company's new product.

What is the BEST advice the regulatory affairs professional can provide to minimize the impact of this guideline on the successful registration of the new product?

A. The company should consult with relevant regulatory authorities to determine the potential impact on the current registration plan.

B. The new guideline has no impact on the current registration plan, but the company must be prepared to defend its decision.

C. The new guideline has no impact on the current registration plan since all relevant registration studies are almost completed.

D. The company should initiate the required pediatric studies immediately to avoid costly delays to the current registration plan.

In preparation for the development of a new line of products, a regulatory affairs professional is asked to prepare a short presentation for senior management. Which of the following topics is MOST important to cover?

A. Potential clinical sites for the Phase III clinical trial

B. Regulatory requirements for labeling and packaging

C. Capacity of the manufacturing facilities to fully produce the new product

D. Previous actions taken by regulatory authorities on similar products

Which question is pertinent to demonstrate a new pharmaceutical's effectiveness during evaluation by a reimbursement agency?

A. "Is the product profitable for the manufacturer?"

B. "Is the product better than currently available alternatives?"

C. "Has the product been approved for morand4nan 10 years?"

D. "Is the product an established gold standard?"

As a member of the product launch review committee, a regulatory affairs professional discovers a major issue with the labeling of a product prior to production. In addition to informing the committee, which is the BEST approach to address the issue?

A. Inform the regulatory authorities.

B. Delay the start of product production.

C. Correct the label text.

D. Abort the product launch.

A company is developing a new medical device using innovative technology. Which of the following is MOST critical in working with regulatory authorities?

A. Documented agreement

B. Frequent communication

C. Early collaboration

D. Follow-up meeting after submission

The regulatory authority contacts the regulatory affairs professional regarding a complaint about a drug produced by the company. A consumer reported to the regulatory authority that the tablets have a slightly different color and break easily.

Which of the following actions should the regulatory affairs professional take?

A. Ask that the regulatory authority provide the batch number printed on the packaging of the affected product.

B. Ask that the regulatory authority provide the actual product subject to the complaint.

C. Respond to the regulatory authority that the product subject to the complaint is most likely acounterfeit product.

D. Respond to the regulatory authority that the company will provide copies of the relevant QCrecords for batch release.

According to ICH, how many stability time points are normally required to establish a two- year shelf life for a product?

A. 3

B. 5

C. 7

D. 9

In which section of the ICH Common Technical Document will the overview of clinical data appear?

A. Module 1

B. Module 2

C. Module 3

D. Module 4

A regulatory authority announces an inspection of a regulatory affairs professional's facility during a holiday season when most of the staff Is not available. What is the MOST practical approach to this dilemma?

A. Negotiate with colleagues and the authority to find a better time.

B. Insist that key personnel be available for the inspection.

C. Inform the authority that the time is not suitable and request a new time

D. Arrange for an inspection without all intended personnel.